Seaweed compound shows major methane cuts in beef cattle
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-May-2026 20:15 ET (25-May-2026 00:15 GMT/UTC)
Adelaide University researchers have demonstrated that a naturally derived seaweed compound can dramatically reduce methane emissions from beef cattle raised in extensive grazing systems, without harming calves.
Kyoto, Japan -- While modern life includes many conveniences, humans are still incessantly exposed to a variety of metabolic stresses we have never experienced before. Our immune systems are constantly trying to protect us, and CD8⁺ T cells in particular -- also known as killer T cells -- play an essential role in attacking tumors.
A team of researchers from Kyoto University's Center for Cancer Immunotherapy and Immunobiology, CCII, and the RIKEN Center for Integrative Medical Sciences was motivated to investigate how metabolic stress can persist in the immune system and its consequences, particularly on anti-tumor immunity.
"Since each one of us experiences variable types of stress throughout our lives, we were interested in finding where and how that stress may influence our health," says first author Masaki Tajima of CCII.
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
The study, involving over 8,000 patients, is the only multi-centre randomised controlled trial (RCT) in a hospital setting to evaluate this approach and the largest RCT in this setting to date. The proportion of patients receiving oral care increased from 15.9% in the control to 61.5% in the intervention, with audits showing oral care was undertaken an average of 1.5 times per day.
Phase I trial provides early clinical proof-of-concept supporting the combination of zedoresertib and lunresertib in certain advanced solid tumors
Zedoresertib, which targets WEE1, and lunresertib, a PKMYT1 inhibitor, are both investigational therapies that create synthetic lethality by blocking cell cycle proteins
Combination achieved notable responses in ovarian cancer at the preliminary recommended Phase II dose, with a 50% overall response rate across all patients and a 60% rate in patients with CCNE1 amplification
This combination has been granted FDA Fast Track Designation in patients with ovarian cancer harboring CCNE1 amplification, FBXW7 or PPP2R1A deleterious mutations
Nutritional epidemiology faces challenges like recall bias and confounding. Advances in AI, image recognition, and multi-omics now enable precision nutrition through personalized interventions and digital twins. The field is also shifting toward sustainable nutrition, promoting planetary health diets to protect the environment.